{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:07:24Z","timestamp":1791284844829,"version":"4.1.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Despite hydroxyurea being an established treatment for sickle cell disease (SCD), it remains underused. The recent approval of the disease-modifying treatments (DMTs) l<\/jats:sc>-glutamine, crizanlizumab, and voxelotor underscores the need to understand the uptake of DMTs in the current treatment landscape.<\/jats:p><\/jats:sec>Objective<\/jats:title>To explore characteristics that may be associated with DMT use and to describe observed patterns of yearly DMT use from 2014 to 2021.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional study used administrative claims data from Optum\u2019s deidentified Clinformatics Data Mart Database from January 1, 2014, to September 30, 2021, to identify adults and children with SCD. Data were analyzed from August 1, 2022, to August 28, 2023.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Use of DMTs.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Patient characteristics across groups with varying patterns of DMT use and yearly patterns of prescription fills for hydroxyurea, crizanlizumab, voxelotor, and l<\/jats:sc>-glutamine.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 5022 beneficiaries with SCD (2081 [41.4%] aged 18-45 years; 2929 [58.3%] female) were included in sample A (144 [2.9%] inconsistent users, 274 [5.5%] incident users, 892 [17.8%] consistent users, and 3712 [73.9%] non-DMT users). Inconsistent users had a higher prevalence of vaso-occlusive crises (mean [SD], 3.7 [4.7]), splenic complications (6 of 144 [4.2%]), pulmonary complications (36 of 144 [25.0%]), kidney disease (21 of 144 [14.6%]), acute chest syndrome (18 of 144 [12.5%]), and health care visits (eg, mean [SD] inpatient visits, 7.0 [10.7]) compared with the other use groups. Non-DMT users had the lowest prevalence of vaso-occlusive crises (mean [SD], 0.8 [2.4]), acute chest syndrome (109 of 3712 [2.9%]), and inpatient (mean [SD], 2.0 [6.6]) and emergency department (mean [SD], 0.7 [3.1]) visits and the highest proportion of adults 65 years and older (593 of 3712 [16.0%]). In sample B (6387 beneficiaries with SCD), hydroxyurea use modestly increased from 428 of 2188 participants (19.6%) in 2014 to 701 of 2880 (24.3%) in 2021. Use of l<\/jats:sc>-glutamine increased briefly but gradually decreased throughout the study period. In 2021, out of 2880 participants, 102 (3.5%) had at least 1 fill for crizanlizumab and 131 (4.6%) had at least 1 fill for voxelotor. Overall, total DMT use increased from 428 of 2188 participants (19.6%) in 2014 to 815 of 2880 patients (28.3%) in 2021.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cross-sectional analysis of adults and children with SCD, uptake of DMTs remained low from 2014 to 2021, despite the approval of newer therapies. Notable differences in patient characteristics across varied DMT exposure types necessitate further exploration into factors that facilitate DMT use and the creation of strategies to enhance DMT uptake.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.44546","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T16:34:55Z","timestamp":1700670895000},"page":"e2344546","source":"Crossref","is-referenced-by-count":38,"title":["Use of Disease-Modifying Treatments in Patients With Sickle Cell Disease"],"prefix":"10.1001","volume":"6","author":[{"given":"Terri Victoria","family":"Newman","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingye","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangho","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Jonassaint","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra L.","family":"Kane-Gill","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico M.","family":"Novelli","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"},{"name":"Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"issue":"1","key":"zoi231302r1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.2022.10233","article-title":"Sickle cell disease: a review.","volume":"328","author":"Kavanagh","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"zoi231302r2","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3324\/haematol.2018.207357","article-title":"Emerging disease-modifying therapies for sickle cell disease.","volume":"104","author":"Carden","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"zoi231302r3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41573-018-0003-2","article-title":"Therapeutic strategies for sickle cell disease: towards a multi-agent approach.","volume":"18","author":"Telen","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"20","key":"zoi231302r4","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia.","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi231302r5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/phar.v40.6","article-title":"Systematic review of crizanlizumab: a new parenteral option to reduce vaso-occlusive pain crises in patients with sickle cell disease.","volume":"40","author":"Han","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"51","key":"zoi231302r6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018225","article-title":"The role of hydroxyurea to prevent silent stroke in sickle cell disease: systematic review and meta-analysis.","volume":"98","author":"Hasson","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"zoi231302r7","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/853835","article-title":"Attitudes toward management of sickle cell disease and its complications: a national survey of academic family physicians.","volume":"2015","author":"Mainous","year":"2015","journal-title":"Anemia"},{"issue":"1","key":"zoi231302r8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12955-019-1225-7","article-title":"Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.","volume":"17","author":"Shah","year":"2019","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"zoi231302r9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.36469\/00001","article-title":"Medical resource use and costs of treating sickle cell-related vaso-occlusive crisis episodes: a retrospective claims study.","volume":"7","author":"Shah","year":"2020","journal-title":"J Health Econ Outcomes Res"},{"key":"zoi231302r10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2020-143434","article-title":"Real world evidence of prescription patterns and effect of Oxbryta (voxelotor) for patients with sickle cell disease.","volume":"136","author":"Shah","year":"2020","journal-title":"Blood"},{"key":"zoi231302r11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood-2020-140525","article-title":"Real-world effectiveness of voxelotor for treating sickle cell disease in the US.","volume":"136","author":"Zaidi","year":"2020","journal-title":"Blood"},{"issue":"16","key":"zoi231302r13","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1001\/jama.2015.3075","article-title":"Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea.","volume":"313","author":"Stettler","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"zoi231302r14","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/jha2.v3.4","article-title":"Treatment patterns and burden of complications associated with sickle cell disease: a US retrospective claims analysis.","volume":"3","author":"Manwani","year":"2022","journal-title":"EJHaem"},{"issue":"5","key":"zoi231302r15","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/pbc.v60.5","article-title":"Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.","volume":"60","author":"Blinder","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"zoi231302r16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12974\/2312-5411.2021.08.1","article-title":"Outcomes and barriers to use of novel sickle cell therapeutic agents in a community health center.","volume":"8","author":"Metzger","year":"2021","journal-title":"J Hematol Res"},{"issue":"12","key":"zoi231302r17","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.v67.12","article-title":"Administrative data identify sickle cell disease: a critical review of approaches in US health services research.","volume":"67","author":"Grosse","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"zoi231302r18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1586\/ehm.10.22","article-title":"Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities.","volume":"3","author":"Brandow","year":"2010","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"zoi231302r19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/0033354919881438","article-title":"Reducing health care disparities in sickle cell disease: a review.","volume":"134","author":"Lee","year":"2019","journal-title":"Public Health Rep"},{"issue":"10","key":"zoi231302r20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"key":"zoi231302r12","unstructured":"Bradt? P, Spackman? E, Synnott? PG, . Crizanlizumab, voxelotor, and l-glutamine for sickle cell disease: effectiveness and value. Institute for Clinical and Economic Review 23. Updated February 9, 2021. Accessed January 2021. https:\/\/icer.org\/wp-content\/uploads\/2021\/02\/ICER_SCD_Evidence-Report_031220-FOR-PUBLICATION.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2812261\/newman_2023_oi_231302_1700083503.72801.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T16:34:58Z","timestamp":1700670898000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2812261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.44546","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]}}}